Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients

Fig. 2

Association between TRF2 and VEGF-A expression in CRC patients. a and b Immunohistochemical (IHC) score of CRC samples labelled with the indicated antibodies. a Representative TMA sections stained for TRF2. Depending on the intensity of nuclear immunoreactivity, tumor samples were classified as negative (score 0), low (score 1+), medium (score 2+), or high (score 3+). b Representative images of CRC samples stained for VEGF-A. Samples’ classification was based on the intensity of the cytoplasmic immunostaining: negative (score 0), faint (score 1+), moderate (score 2+) or intense (score 3+). c Histogram showing the percentage of patients divided on the basis TRF2 and VEGF-A immuhistochemical scores, respectively. Score 0 (blue), 1+ (orange), 2+ (grey) and 3+ (yellow). d Upper panel - pie charts showing the distribution of VEGF-A low (VEGF-AL, score 0/1+) and VEGF-A high, (VEGF-AH, score 2+/3+) in the sub-populations of TRF2 low (TRF2L, score 0/1+) and TRF2 high (TRF2H, score 2+/3+) patients (***P < 0.001; χ2 test). Lower panel – IHC evaluation of TRF2 and VEGF-A expression in two representative CRC samples showing (1) low levels of VEGF-A and TRF2 (VEGF-AL/TRF2L) and (2) high levels of VEGF-A and TRF2 (VEGF-AH/TRF2H). Scale bar: 100 μm

Back to article page